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Abstract
Background: We evaluated the prognostic significance and universal validity of the total number of evaluated
lymph nodes (ELN), number of positive lymph nodes (PLN), lymph node ratio (LNR), and log odds of positive
lymph nodes (LODDS) in a relatively large and homogenous cohort of surgically treated pancreatic ductal
adenocarcinoma (PDAC) patients.
Methods: Prospectively accrued data were retrospectively analyzed for 282 PDAC patients who had
pancreaticoduodenectomy (PD) at our institution. Long-term survival was analyzed according to the ELN,
PLN, LNR, and LODDS.
Results: Of these patients, 168 patients (59.5 %) had LN metastasis (N1). Mean ELN and PLN were 13.5 and
1.6, respectively. LN positivity correlated with a greater number of evaluated lymph nodes; positive lymph
nodes were identified in 61.4 % of the patients with ELN ≥ 13 compared with 44.9 % of the patients with
ELN < 13 (p = 0.014). Median overall survival (OS) and 5-year OS rate were higher in N0 than in N1 patients,
22.4 vs. 18.7 months and 35 vs. 11 %, respectively (p = 0.008). Mean LNR was 0.12; 91 patients (54.1 %) had
LNR < 0.3. Among the N1 patients, median OS was comparable in those with LNR ≥ 0.3 vs. LNR < 0.3 (16.7
vs. 14.1 months, p = 0.950). Neither LODDS nor various ELN and PLN cutoff values provided more discriminative
information within the group of N1 patients.
Conclusions: Our data confirms that lymph node positivity strongly reflects PDAC biology and thus patient outcome.
While a higher number of evaluated lymph nodes may provide a more accurate nodal staging, it does not have any
prognostic value among N1 patients. Similarly, PLN, LNR, and LODDS had limited prognostic relevance.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer-related mortality in the USA [1],
exhibiting an aggressive biological behavior with a 5-year
overall survival of 7 % [1]. Currently, the only potential
curative option for PDAC is surgery followed by adju-
vant chemotherapy. Yet, even after this multimodality
treatment, disease will recur in over 80 % of these pa-
tients [2, 3]. Identification of patients at higher risk of
disease recurrence following surgery is of utmost im-
portance and may lead to better allocation of patients to
adjuvant therapies.
To date, various prognostic factors have been identi-
fied and included in pancreatic cancer staging systems;
of them, lymphatic metastasis is constantly considered a
powerful indicator of advanced stage and adverse out-
come [4–11]. Evaluating lymph node involvement is
complex and is affected by the extent of lymphadenec-
tomy as well as the thoroughness of the pathology ana-
lysis of the surgical specimen [6, 7]. Currently, lymph
node status is defined by the American Joint Committee
on Cancer (AJCC) staging system as either negative (N0)
or positive (N1) [4–7]. However, several studies
suggested that lymph node status can be further re-
fined by either the number of evaluated lymph nodes
(ELN) [6, 12–14], number of positive lymph nodes
(PLN) [6, 15–18], lymph node ratio (LNR) [6, 13, 19–21],
or log odds of positive lymph nodes (LODDS) [19]. Never-
theless, data regarding these nodal staging parameters
remain conflicting.
We aimed to evaluate the prognostic value of these nodal
staging methods on a relatively large and homogenous
cohort of consecutive patients undergoing curative pan-
creaticoduodenectomy (PD) at a single institution.
Methods
Study cohort
The study was conducted at the Tel Aviv Sourasky Med-
ical Center, Tel Aviv, Israel (TLVMC). The Department of
Surgery at the TLVMC serves as a national tertiary referral
center. Between 1995 and 2013, 317 patients underwent
PD with curative intent for PDAC. Seven patients
receiving neoadjuvant chemotherapy or radiation were
excluded. Data was collected retrospectively (between
1995 and 2010) and prospectively (between 2010 and
2013). Included in the current study are complete clinical
and survival data for 282 patients.
The study was approved by the Institutional Review
Board (#0052-15-TLV).
Surgical approach and pathological work-up
We perform a standard lymphadenectomy in patients
undergoing PD for suspected PDAC. This includes re-
trieval of peripancreatic LN and clearance of LN in the
hepatoduodenal ligament along the portal vein and hep-
atic artery to the right side of the celiac trunk and
complete clearance of LN on the right side of the upper
aspect of the superior mesenteric artery and vein. Our
institutional pathologic work-up includes the evaluation
of all resected LN. These are completely embedded and
labeled according to the International Union Against
Cancer TNM LN grouping [22].
Data collection
The following data was collected for each patient:
demographics, tumor characteristics, operative details,
pathologic margin status, presence of lymphovascular
invasion, perineural invasion, lymph node status, sur-
vival data, and oncology treatment. Data on tumor
size, ELN, and PLN were obtained from a review of
all pathology reports. Staging was determined accord-
ing to AJCC (sixth edition).
Lymph node classifications
LNR was determined by dividing the total number of
lymph nodes harboring a metastasis by the total number of
nodes examined. Patients were sub-classified using previ-
ously reported cutoff values of ELN, PLN, or LNR [6–21].
LODDS was calculated as previously described: log [(PLN
+ 0.5)/(ELN − PLN+ 0.5)], 0.5 is added to both the
numerator and denominator to avoid singularity [19, 23].
Patients were subdivided into four subgroups according to
their LODDS value: LODDS1 (LODDS ≤ −1.5), LODDS2
(−1.5 < LODDS ≤ −1.0), LODDS3 (−1.0 < LODDS ≤ −0.5),
LODDS4 (LODDS > −0.5) [24].
Statistical analyses
The endpoint of this study was overall survival (OS),
which was calculated as the elapsed time from pancreati-
coduodenectomy to death; data was collected at the time
of the last follow-up. Student’s t test was used for com-
parison of continuous variables, chi-square test was used
for comparing categorical variables, and Kaplan-Meier
curves were constructed to determine OS time. Log-
rank test was used to compare OS between subgroups of
patients. Univariable Cox proportional hazard regression
models were examined to assess the ability of patient
characteristics to predict OS. A multivariable Cox model
was performed using backward elimination with p value
cutoff of 0.05. All computations were carried out in
SPSS ver. 17 (SPSS Inc., Chicago, IL).
Results
Patients and tumor characteristics
During the study period, 282 consecutive patients had
PD for PDAC. Patients and tumor characteristics are
depicted in Table 1. One hundred and forty-six patients
were men (52 %); median age at the time of surgery was
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67 years (range, 34–85). Four (1.4 %), nine (3.2 %), and
ten (3.5 %) patients died within 30, 60, and 90 days of
resection, respectively. Mean tumor size was 3.1 ±
1.6 cm, most patients had T2 or T3 carcinoma (n = 225;
80 %), 119 carcinomas (42 %) were categorized as poorly
differentiated, and negative microscopic margins were
recorded in 221 patients (79 %). Of the 282 patients, 144
patients (51 %) had negative lymph nodes (N0), whereas
138 patients (49 %) had lymph node metastasis (N1).
The majority of N1 patients (66 %, n = 91) had LNR <
0.3. The mean LODDS value was 0.79 ± 0.47 (range,
−1.72 to 1.11). One hundred and eighty patients (63.8 %)
received adjuvant chemotherapy, mostly gemcitabine as
a single agent (n = 129) or in combination with cisplati-
num (n = 27). Others were treated with 5-FU leucoverin
(n = 17), FOLFIRI (n = 5), and FOLFIRINOX (n = 2).
Survival in relation to stage and tumor characteristics
At a median follow-up of 22 months (range, 1–159), the
median survival for the entire cohort was 21 months
(95 % CI, 17.7–24.2) and the 1-, 3-, and 5-year OS rates
are 72, 31, and 23 %, respectively (Fig. 1). Evaluating N1
vs. N0 patients, median survival and 5-year OS rate were
20 vs. 22 months and 9 vs. 34 %, respectively (p = 0.008;
Fig. 1). Multivariate proportional hazard regression (Cox
model) analysis identified tumor size larger than 3 cm
(HR 1.29, 95 % CI, 1.05–4.05), poor differentiation (HR
1.58, 95 % CI, 1.14–3.38), lymph node metastasis (N1;
HR 3.47, 95 % CI, 1.5–7.36), and positive resection
margins (R1; HR 1.41, 95 % CI, 1.03–6.77) as adverse
prognosticators (Table 2).
Survival in relation to the number of evaluated lymph
nodes
The mean number of ELN was 13.5 (range, 1–38) and
did not differ over the time course of the study (13;
range, 1–35; between 1995 and 2007 vs. 13.8; range,
1–38, between 2007 and 2013; p = 0.51). Using a number
of cutoff values, Kaplan-Meier survival analyses did not
show any association between ELN and survival in N1
patients (Fig. 2a); median survival for the groups of
patients with the highest vs. the lowest cutoff values of
ELN ≥ 17 (n = 28) and ELN < 6 (n = 22) were 15 months
(95 % CI, 8.1–22) vs. 18 months (95 % CI, 14.3–23),
respectively (Fig. 2b, p = 0.86).
Although the number of ELN did not predict survival,
it correlated with the nodal status. Thus, ELN ≥ 13 was
noted in 51 (37 %) of the N1 patients, but only in 31
(22 %) of the N0 patients (p = 0.014).
Survival in relation to the number of positive lymph
nodes
Mean PLN was 1.6, with 47 patients (37 %) having three or
more PLN. PLN correlated with the number of ELN. Thus,
26 % of patients with >12 ELN had three or more PLN
compared to 13 % in the group of ≤12 ELN (p = 0.01).
Using a cutoff value of 3, Kaplan-Meier survival analysis
did not demonstrate a correlation between the number of
PLN and survival. As depicted in Fig. 2c, median OS of
PLN ≥ 3 and PLN < 3 was similar (20 months in both
groups, p = 0.8). These results were unrelated to the num-
ber of ELN; PLN ≥ 3 did not emerge as a significant
prognosticator in either the group of ELN ≥ 17 patients (the
highest evaluated ELN cutoff value) or within the ELN < 6
patients (the lowest evaluated ELN cutoff value).
Survival in relation to the lymph node ratio
The association between LNR ≥ 0.3 and OS was evalu-
ated in the whole cohort of N1 patients. As depicted
in Fig. 2d, median survival rates of patients with LNR
< 0.3 and LNR ≥ 0.3 were 20 vs. 19 months,
Table 1 Patients clinical and pathological characteristics
Variable No. of patients (%)
Age, years, median (range) 67 (34–85)
Gender
Male (%) 146 (51.8 %)
Female (%) 136 (49.2 %)
Vascular resection 17 (6 %)
R0 resection 221 (78.4 %)
Average tumor size 3.14 (SD 1.58)
Differentiation
Well 55 (19.5 %)
Intermediate 86 (30.5 %)
Poor 119 (42.2 %)
Unknown 22 (7.8 %)
Microvascular invasion
Present 106 (37.6 %)
Absent 123 (43.6 %)
Unknown 53 (18.8 %)
Perineural Invasion
Present 214 (75.9 %)
Absent 42 (14.9 %)
Unknown 26 (9.2 %)
Lymph node status
N0 144 (51.1 %)
N1 138 (48.9 %)
ELN, mean 13.5 (SD 5.2)
ELN > 12 82 (29.1 %)
PLN, mean 1.6 (SD 0.9)
LNR≥ 0.3 47 (34 %)
LODDS, mean −0.79 (SD 0.47)
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respectively (p = 0.95). Additional cutoff values were
also examined, and none has emerged as a significant
predictor of OS.
In order to minimize a potential stage migration effect
caused by inadequate LN sampling, we examined the as-
sociation between LNR ≥ 0.3 and OS in patients with
ELN > 12. LNR did not predict OS in these patients, and
further analyses failed to identify any minimum number
of ELN as a predictor of survival.
Survival in relation to log odds of positive lymph nodes
(LODDS)
Patients were categorized into four groups according to
their LODDS: LODDS1 (LODDS ≤ −1.5), LODDS2 (−1.5
< LODDS ≤ −1.0), LODDS3 (−1.0 < LODDS ≤ −0.5), and
LODDS4 (LODDS > −0.5). All patients categorized as
LODDS1 had no LN involvement. Therefore, only the
groups LODDS2–4 were included in the analysis. LODDS
was not associated with OS in the whole group (Fig. 3a, p
= 0.47) or in patients with ELN > 12 (Fig. 3b, p = 0.75).
Additionally, no association between LODDS and OS was
noted in patients with LNR ≥ 0.3 or LNR < 0.3.
Discussion
Numerous studies have shown that involvement of
regional lymph nodes is an imperative adverse prognos-
ticator in PDAC [4–11]. Yet, prognosis of patients with
N1 disease may vary widely and more accurate classifica-
tion of these patients may better allocate them to appro-
priate adjuvant treatment and a better design of clinical
trials. Therefore, we examined the association between
various nodal classifications and OS in a relatively large
cohort of PDAC patients.
A major advantage of the current study is the analysis
of a relatively homogenous cohort of patients operated
in a single institution by a select number of surgeons
experienced in pancreatic surgery. Similarly, the high
volume of pancreatic operations performed in our insti-
tution (approximately 80 per year) enabled our gastro-
intestinal (GI) pathologists to gain a vast experience in
the evaluation of PDAC pathological specimens of PD.
Fig. 1 Pancreaticoduodenectomy for ductal adenocarcinoma outcome analysis. Kaplan-Meier overall survival curves for the whole cohort (red line)
and according to N0 (blue line) versus N1 (green line) status (p = 0.008)
Table 2 Predictive factors of survival following PD for PDAC
multivariate analysis
Prognostic factor HR 95 % CI p value
Age > 70 years 1.19 0.77–1.55 0.1
Tumor size > 3 cm 1.29 1.05–4.05 0.01
Tumor differentiation
Well 1.00
Moderate 1.23 0.67–3.79 0.26
Poor 1.58 1.14–3.38 0.02
R1 resection 1.41 1.03–6.77 0.05
Lymph node metastasis 3.47 1.50–7.36 0.001
ELN 1.07 0.89–4.75 0.83
PLN 1.39 1.03–6.22 0.12
LNR 0.97 0.71–3.98 0.35
LODDS 1.62 1.11–2.49 0.09
Perineural invasion 1.12 0.63–1.71 0.34
Microvascular invasion 0.97 0.72–1.44 0.48
HR hazard ration, CI confidence interval
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Thus, the combination of adequate surgery and patho-
logical evaluation by trained teams eliminates various
possible confounding factors.
Nodal status is affected by the total number of
retrieved and evaluated lymph nodes, which is strongly
reliant upon adequate lymphadenectomy and a thorough
pathological evaluation. Various cutoff numbers have
been used to evaluate the prognostic significance of ELN
with inconsistent results [6, 12–14]. In agreement with
previous studies, our data demonstrate an association
between increased ELN and N1 status [6, 7]; yet, ELN by
itself did not correlate with OS among N1 patients. The
latter observation correlates with the findings of
Vuarnesson et al. who demonstrated that an ELN of 16
is required to assess nodal status, yet OS was not af-
fected by the number of evaluated lymph nodes in both
N0 and N1 patients [7]. A subset analysis of our N0
patients suggested an association between high ELN
and increased OS (data not shown), possibly due to a
false classification of N0 patients with a low ELN as
node negative. Thus, higher ELN may simply increase
the accuracy of nodal staging. These data also suggests
that any analysis of N0 and N1 patients grouped to-
gether might be biased due to nodal staging inaccur-
acies and data based on such analyses should be
interpreted with caution.
A recent analysis of the SEER data, including over
15,000 patients who were operated for PDAC, suggested
an association between ELN, PLN, and LNR with OS
[6]. Similarly, several series also suggested an association
between ELN and outcomes within N1 patients calling
for extended lymphadenectomy in PDAC patients
[25–28]. Yet, the role of extended lymphadenectomy
in PDAC remains debatable [29–31]. In 1989, Manabe
et al. have shown a significant benefit of radical
lymphadenectomy arguing that sufficient lymph node
Fig. 2 Kaplan-Meier overall survival curves according to ELN < 13 (green line) vs. ELN≥ 13 (blue line; a p = 0.441), ELN < 6 (green line) vs. ELN≥ 17
(blue line; b p = 0.863), PLN < 3 (green line) vs. PLN≥ 3 (blue line; c p = 0.797), and LNR < 0.3 (green line) vs. LNR ≥ 0.3 (blue line; d p = 0.95)
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clearance is indispensible to cure PDAC patients [27].
More recent data suggest the opposite; in 2005, the
results of a prospective randomized trial were pub-
lished by Farnell et al. who showed no survival differ-
ence in standard versus extended lymphadenectomy
during PD [29]. Nimura et al. conducted a multicen-
ter RCT in a strict setting, showing that extended
lymphadenectomy in radical PD did not benefit long-
term survival in patients with resectable pancreatic
head cancer [30]. These data indicate that removal of
positive lymph nodes from remote basins probably
does not affect PDAC patient outcomes. Taken to-
gether with our data, it seems that the role of the
surgeon in clearing all metastatic lymph nodes is truly
limited.
During the last decade, LNR emerged as a prominent
nodal prognostic factor in GI cancers, particularly in
gastric cancer [6, 13, 19–21, 32, 33]. In accord with this
trend, several reports suggested an association between
LNR and survival in PDAC [6, 20, 32, 34–38]. Not
surprisingly, the cutoff LNR values suggested by these
papers are inconsistent: Showalter el al. have shown that
LNR > 33 % is associated with adverse prognosis [16],
Ashfaq et al. demonstrated that PDAC patients with
LNR > 0.1 have shorter OS [12], whereas Liu et al.
suggested the cutoff of LNR ≥ 0.4 as a predictor for worse
outcome [13]. Many of these studies included N0 patients
in their analysis, for whom LNR is irrelevant. Our data
suggest no association between LNR and survival. This
may be attributed to the exclusion of N0 patients from the
current analysis. In agreement with our findings, Kang et
al. analyzed a cohort of nearly 400 PDAC patients and also
failed to show an association between PLN and LNR and
prognosis [15].
LODDS is a novel indicator of lymph node status, de-
veloped with the aim of improving the accuracy of nodal
classification for prognostic assessment. LODDS has sev-
eral theoretical advantages over LNR. Mathematically,
this logarithmic function distinguishes between patients
with LNR = 0 (N0 patients) as well as patients with simi-
lar LNR but different PLN and/or ELN values (i.e., 2/4
and 5/10). LODDS has been investigated as a prognostic
factor in several cancers [38–42]; however, data
concerning its predictive role in pancreatic cancer is
scarce. La Torre et al. analyzed a series of 143 PDAC
patients who had pancreatic resection. They concluded
that LODDS and LNR are more powerful predictors of
survival than lymph node status and that LODDS allows
better prognostic stratification compared with LNR in
node-negative patients [19]. The results of the present
study question the potential role of LODDS as a prog-
nostic factor in N1 PDAC patients, unrelated to nodal
status, ELN, or LNR.
The major limitation of the present study is its retro-
spective nature. All nodal parameters were dependent
on past evaluation of dedicated pathologists that worked
with our surgical team using different techniques over a
period of almost two decades. In addition, surgical ad-
equacy, as well as patient selection for PD, has changed
over this time period. Another potential weakness is that
the average number of evaluated lymph nodes is rela-
tively low compared to several other studies [6, 36, 43];
yet, our subset analyses in patients with ELN > 12 and
even in a subgroup of patients with ELN > 15 did not
alter our results.
Since not all patients included in the present study co-
hort have been treated with post-operative chemother-
apy, the results might be biased. Adjuvant chemotherapy
Fig. 3 Kaplan-Meier overall survival curves according to LODDS within the whole cohort of N1 patients (a p = 0.471), LODDS within the group of
patients with ELN≥ 13 (b p = 0.753)
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has become the standard of care for PDAC patients only
after the publication of the CONKO-001 trial in 2007.
Per institutional guidelines, no patient received adjuvant
therapy prior to that period, while since 2008, all pa-
tients received treatment, regardless of tumor stage.
While some deviations from guidelines may occur, it is
still likely that administration of adjuvant treatment is
not a major confounding factor in this study.
Lastly, data concerning post-recurrence therapy was
not collected and is not included in our analysis. While
the pattern of oncology therapy for PDAC has changed
dramatically during the study period (gemcitabine in
1997, FOLFIRINOX since 2011), the median overall
survival of patients with metastatic disease increased from
about 5 months to only 11 months. Therefore, any poten-
tial effects of the first- and second-line therapy on survival
are small. Moreover, all patients were treated at our insti-
tution according to similar guidelines and treatment for
metastatic disease was not affected by nodal status at
presentation. Therefore, it is likely that the subsequent
oncology treatments did not significantly affect our con-
clusions regarding the role of lymph node involvement.
Conclusions
Pancreaticoduodenectomy with conventional lymphade-
nectomy remains the primary method of locoregional
control of PDAC and is the only potentially curative treat-
ment for this disease. Our present study demonstrates that
the presence of lymph node metastasis is an independent
adverse prognosticator, regardless of the total number of
ELN, number of PLN, LN ratio, or LODDS of positive
lymph nodes. The data does not refute the role of
adequate lymphadenectomy or the need for a meticulous
evaluation of lymph node status by the pathologist.
However, it implies that any presence of nodal involve-
ment represents a very aggressive biological behavior of
the primary tumor. Clearly, further clinical and molecular
investigation is needed in order to augment our present
understanding of lymphatic metastasis biology and to
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